Acri Capital Acquisition Corporation Announces Extension of the Deadline for an Initial Business Combination
12 juin 2024 16h00 HE | Acri Capital Acquisition Corporation
Austin, Texas, June 12, 2024 (GLOBE NEWSWIRE) -- Acri Capital Acquisition Corporation (the “Company”) (Nasdaq: ACAC), a special purpose acquisition company, today announced that, in order to extend...
Nurix.png
Nurix Therapeutics Announces Board Chair Transition
20 mai 2024 16h00 HE | Nurix Therapeutics, Inc.
David L. Lacey steps down from chair role and will remain board member and retain committee leadership roles Current board member Julia P. Gregory unanimously elected new board chair SAN FRANCISCO,...
Acri Capital Acquisition Corporation Announces Confidential Submission of Draft Registration Statement on Form S-4 and Extension of the Deadline for an Initial Business Combination
10 avr. 2024 16h30 HE | Acri Capital Acquisition Corporation
Austin, Texas, April 10, 2024 (GLOBE NEWSWIRE) -- Acri Capital Acquisition Corporation (the “Company”) (Nasdaq: ACAC), a special purpose acquisition company, today announced that, in relation to its...
Acri Capital Acquisition Corporation Announces Extension of the Deadline for an Initial Business Combination
13 mars 2024 16h05 HE | Acri Capital Acquisition Corporation
Austin, Texas, March 13, 2024 (GLOBE NEWSWIRE) -- Acri Capital Acquisition Corporation (the “Company”) (Nasdaq: ACAC), a special purpose acquisition company, today announced that, in order to extend...
ContraFect_LOGO_Web.jpg
ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical Study
16 oct. 2023 07h30 HE | ContraFect Corporation
YONKERS, N.Y., Oct. 16, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
22157.jpg
Global Antibiotic Resistance Markets, 2023-2027: Beyond Antibiotics - Exploring Cutting-Edge Trends in AMR Solutions
05 oct. 2023 06h43 HE | Research and Markets
Dublin, Oct. 05, 2023 (GLOBE NEWSWIRE) -- The "Antibiotic Resistance Markets - Therapeutics by Pathogen and Therapy Type. With Situation Analysis, Executive & Investor Guides &...
ContraFect_LOGO_Web.jpg
ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development
19 sept. 2023 08h30 HE | ContraFect Corporation
YONKERS, New York, Sept. 19, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
Press-Page - 2
41% of U.S. Workers Say They are Most Productive Outside of 9-5 Work Hours, According to Research from Fiverr
19 sept. 2023 08h00 HE | Fiverr International Ltd.
NEW YORK, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Fiverr International Ltd. (NYSE: FVRR), the company that is revolutionizing how the world works together, has compiled findings from a study exploring...
ContraFect_LOGO_Web.jpg
ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370
18 sept. 2023 07h30 HE | ContraFect Corporation
YONKERS, N.Y., Sept. 18, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...